Literature DB >> 18766190

Birth and parental characteristics and risk of neuroblastoma in a population-based Norwegian cohort study.

T Bjørge1, A Engeland, S Tretli, I Heuch.   

Abstract

In this population-based Norwegian cohort study (2.1 million children), the impact of birth and parental characteristics on the risk of neuroblastoma (178 cases) was evaluated. In children below the age of 18 months, there was an increased neuroblastoma risk among those with congenital malformations and suggestion of increased risk when the mother had pre-eclampsia.

Entities:  

Mesh:

Year:  2008        PMID: 18766190      PMCID: PMC2567075          DOI: 10.1038/sj.bjc.6604646

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


Neuroblastoma is the most common cancer in children less than 1 year of age, and is the third most common malignancy in childhood (below 5 years of age) in the United States (Goodman ). The incidence of neuroblastoma has increased in some European countries during 1978–1997 (Kaatsch ; Spix ), possibly influenced by changes in identification and reporting of the disease over time. Although there has been substantial improvement in prognosis of well-defined subsets of patients in the past few decades, the long-term survival for children with high-risk disease is still less than 40% (Maris ). Neuroblastoma is an embryonal tumour that originates from primordial neural crest cells that eventually develop into the sympathetic nervous system (SNS) and the adrenal medulla. The tumour almost exclusively occurs in infants and young children. About 50% of the tumours originate in the adrenal gland, another 20% in other areas of the abdomen and about 30% in the sympathetic ganglia in the neck, thorax and pelvis (Huddart and Mann, 1991; Buck ). The most frequent genetic abnormality found in neuroblastoma is the amplification of the MYCN protooncogene, but also other genetic abnormalities have been identified (Maris ). Relatively little is known about the aetiology of neuroblastoma. The peak incidence during early childhood indicates that prenatal and perinatal factors may play an important role in its pathogenesis, but the evidence is rather limited and inconclusive (Hamrick ; Schuz ). In this study, we aimed to evaluate the impact of birth and parental characteristics on the risk of neuroblastoma, both adrenal and non-adrenal, in a large population-based Norwegian cohort study, using data from the medical birth and cancer registries of Norway.

Materials and methods

Study subjects

The Medical Birth Registry of Norway (MBRN) is population-based and contains information on all births in Norway since 1967, defined as all live births and reported foetal deaths of 16 complete weeks of gestation or more. Each record contains information on demographic variables, pregnancy, delivery and the newborn (Irgens, 2000). Data on all deaths registered by Statistics Norway are routinely linked to the birth records. Medical Birth Registry of Norway includes a unique identification number assigned to all live-born children in Norway as well as parents. Since 1953, the Cancer Registry of Norway (CRN) has received information on all cancer patients in the population. The reporting system is based on pathology and cytology reports, clinical records and death certificates, and provides information about site, histological type and stage of disease at the time of diagnosis (The Cancer Registry of Norway, 2008). Through 1992, registration was based on a modified version of ICD-7. Since 1993, ICD-O has been the basis for coding. All live-born children in Norway during the period 1967–2004 (n=2 127 452) were defined as our study cohort. However, twins, triplets and quadruplets were excluded from the analyses. The personal identification number was used to link the two registries to identify all cases of neuroblastoma in children below 15 years of age. For each child, only the first histologically verified malignant tumour was included in the study. All histologically confirmed neuroblastoma in the SNS were included. Neuroblastomas in the central nervous system and in the eye were excluded. Ganglioneuroblastoma and ganglioneuromas were excluded as well. Each person was followed up from date of birth until 15 years of age, emigration, cancer diagnosis (any site), death or until 31 December 2004. Screening for neuroblastoma has never been introduced in Norway.

Statistical analysis

Cox proportional hazards regression models (Cox and Oakes, 1984), with time since birth as the time variable, were fitted to obtain relative risk (RR) estimates of neuroblastoma. Tests for trend in the risk of neuroblastoma were performed by including the variables as continuous variables. In subanalyses, the study cohort was stratified by age (below and above 18 months) according to new risk stratification criteria (Maris ). The statistical package SPSS (SPSS Inc., 2006) was used for estimating RRs of neuroblastoma with 95% confidence intervals (CIs).

Results

Altogether 2 127 452 children (1 092 727 boys and 1 034 725 girls) were included in our study, comprising 25 302 860 person-years. The mean time of follow-up was 11.9 years. A total of 178 children (94 boys and 84 girls) were diagnosed with neuroblastoma during 1967–2004. The primary location of 83 tumours was in the adrenal medulla, whereas 95 tumours were located at non-adrenal sites. Ninety-seven cases (54%) were diagnosed before the age of 18 months, 62 cases between 18 months and 4 years, 15 cases between 5 and 9 years and four cases between 10 and 14 years. The number of adrenal and non-adrenal cases was similar before 5 years of age, thereafter there were more cases of non-adrenal origin. Tables 1 and 2 show results from univariate analyses investigating the relations between birth and parental characteristics and risk of neuroblastoma. There was an increased risk among children with congenital malformations (RR=2.3, 95% CI=1.2–4.8). This increase was restricted to tumours of adrenal origin (RR=3.2, 95% CI=1.3–7.8) and to children diagnosed before the age of 18 months (RR=3.7, 95% CI=1.7–8.0). No other specific association with birth and parental characteristics was observed with regard to location of tumour (adrenal and non-adrenal) (Table 1). Among children having mothers with pre-eclampsia during pregnancy, six developed neuroblastoma during follow-up (RR=1.2, 95% CI=0.5–2.8), all these cases being diagnosed below 18 months of age (RR=2.3, 95% CI=1.0–5.2).
Table 1

Relative risk (RR) of neuroblastoma (adrenal and non-adrenal) with 95% confidence intervals (CIs) obtained in Cox regression analyses with age as the time variable, univariate

  Adrenal medulla
Non-adrenal
All
Total no. of
  N RR (95% CI) N RR (95% CI) N RR (95% CI) person-yearsa
Sex
 Male441.0Referent501.0Referent941.0Referent12 986 975
 Female390.9(0.6–1.4)451.0(0.6–1.4)840.9(0.7–1.3)12 315 885
           
Season of birth
 Winter191.0Referent221.0Referent411.0Referent6 055 108
 Spring211.0(0.5–1.8)220.9(0.5–1.6)430.9(0.6–1.4)6 948 415
 Summer140.7(0.3–1.4)321.4(0.8–2.4)461.1(0.7–1.6)6 377 263
 Autumn291.6(0.9–2.8)190.9(0.5–1.6)481.2(0.8–1.8)5 922 074
           
Birth year
 1967–1976151.0Referent341.0Referent491.0Referent9 048 742
 1977–1986312.5(1.4–4.7)220.8(0.5–1.4)531.3(0.9–2.0)7 367 257
 1987–1996231.6(0.9–3.1)240.8(0.5–1.3)471.0(0.7–1.5)7 103 214
 1997–2004141.7(0.8–3.6)150.9(0.5–1.6)291.1(0.7–1.8)1 783 647
 Test for trend  P=0.07  P=0.4  P=0.5 
           
Gestational age (weeks)
 <3730.8(0.3–2.7)20.5(0.1–2.0)50.6(0.3–1.6)1 093 431
 37–39251.0(0.6–1.6)271.0(0.6–1.5)521.0(0.7–1.4)7 533 126
 40–41381.0Referent431.0Referent811.0Referent11 698 199
 42+161.5(0.8–2.7)141.2(0.6–2.1)301.3(0.9–2.0)3 376 235
 Test for trend  P=0.6  P=0.2  P=0.2 
           
Birth weight (g)
 500–249931.3(0.4–4.5)00.0(0.0-)30.6(0.2–1.9)803 494
 2500–299981.1(0.5–2.5)111.2(0.6–2.4)191.2(0.7–2.0)2 645 261
 3000–3499221.0Referent281.0Referent501.0Referent8 110 752
 3500–3999321.3(0.8–2.2)361.1(0.7–1.9)681.2(0.8–1.7)8 993 123
 4000–4499151.4(0.7–2.7)181.3(0.7–2.4)331.4(0.9–2.1)3 832 887
 4500–630020.8(0.2–3.4)10.3(0.0–2.3)30.5(0.2–1.7)869 990
 Test for trend  P=0.6  P=0.6  P=0.5 
           
Birth length (cm)
 40–49220.6(0.4–1.2)250.8(0.5–1.5)470.7(0.5–1.1)7 514 368
 50231.0Referent201.0Referent431.0Referent5 127 381
 5170.3(0.1–0.8)211.2(0.6–2.2)280.7(0.5–1.2)4 580 532
 52130.8(0.4–1.6)130.9(0.5–1.8)260.8(0.5–1.4)3 634 186
 53–60130.8(0.4–1.5)130.9(0.4–1.8)260.8(0.5–1.3)3 823 916
 Test for trend  P=0.4  P=0.4  P=0.2 
           
Head circumference (cm) b
 <35181.1(0.6–1.9)191.2(0.7–2.1)371.1(0.7–1.7)4 508 997
 35–36301.0Referent291.0Referent591.0Referent7 996 344
 37+171.5(0.8–2.7)121.1(0.6–2.2)291.3(0.8–2.0)2 938 088
 Test for trend  P=0.3  P=1.0  P=0.5 
           
Congenital malformations
 No781.0Referent921.0Referent1701.0Referent24 841 001
 Yes53.2(1.3–7.8)31.6(0.5–5.1)82.3(1.2–4.8)461 860
           
Maternal age (years)
 <2010.2(0.0–1.6)61.2(0.5–2.9)70.7(0.3–1.6)1 326 358
 20–24261.0(0.6–1.7)250.9(0.5–1.5)511.0(0.7–1.4)7 229 682
 25–29341.0Referent361.0Referent701.0Referent8 916 292
 30–34150.7(0.4–1.2)180.8(0.4–1.4)330.7(0.5–1.1)5 394 919
 35+70.7(0.3–1.6)100.9(0.5–1.9)170.8(0.5–1.4)2 419 919
 Test for trend  P=0.4  P=0.6  P=0.4 
           
Parity
 1371.0Referent381.0Referent751.0Referent10 431 465
 2–3370.8(0.5–1.3)451.0(0.6–1.5)820.9(0.6–1.2)12 803 473
 4–581.3(0.6–2.9)81.3(0.6–2.8)161.3(0.8–2.3)1 712 654
 6+11.1(0.2–8.3)22.2(0.5–9.2)31.7(0.5–5.4)255 223
 Test for trend  P=0.8  P=0.9  P=0.9 
           
Pre-eclampsia
 No801.0Referent921.0Referent1721.0Referent24 639 244
 Yes31.3(0.4–4.2)31.2(0.4–3.7)61.2(0.5–2.8)663 616
           
Caesarean section
 No751.0Referent871.0Referent1621.0Referent23 362 347
 Yes81.2(0.6–2.4)81.0(0.5–2.1)161.1(0.6–1.8)1 940 514
           
Paternal age (years)
 <25131.1(0.5–2.1)221.6(0.9–2.8)351.3(0.9–2.1)4 343 748
 25–29331.3(0.8–2.3)240.8(0.5–1.5)571.1(0.7–1.6)8 468 047
 30–34221.0Referent251.0Referent471.0Referent6 959 181
 35–3970.6(0.3–1.5)181.4(0.8–2.6)251.0(0.6–1.7)3 428 839
 40+50.8(0.3–2.2)40.6(0.2–1.7)90.7(0.3–1.4)1 886 960
 Test for trend  P=0.2  P=0.3  P=0.09 

The total number of person-years for some variables may differ due to missing data.

Head circumference has been recorded since 1978.

Table 2

Relative risk (RR) of neuroblastoma with 95% confidence intervals (CIs) obtained in Cox regression analyses, age below and above 18 months, univariate

  ⩽18 months (97 cases)
>18 months (81 cases)
  RR (95% CI) RR (95% CI)
Sex
 Male1.0Referent1.0Referent
 Female0.9(0.6–1.4)1.0(0.6–1.5)
     
Season of birth
 Winter1.0Referent1.0Referent
 Spring1.0(0.6–1.7)0.8(0.4–1.6)
 Summer0.8(0.4–1.4)1.5(0.8–2.9)
 Autumn0.9(0.5–1.6)1.6(0.9–3.0)
     
Birth year
 1967–19761.0Referent1.0Referent
 1977–19861.6(0.9–2.9)1.1(0.6–1.9)
 1987–19961.5(0.9–2.6)0.7(0.4–1.2)
 1997–20041.3(0.7–2.4)1.1(0.6–2.3)
 Test for trend P=0.3 P=0.8
     
Gestational age (weeks)
 <370.6(0.2–2.0)0.7(0.2–2.8)
 37–390.6(0.4–1.0)1.5(0.9–2.5)
 40–411.0Referent1.0Referent
 42+1.2(0.7–2.0)1.6(0.8–3.0)
 Test for trend P=0.4 P=0.5
     
Birth weight (g)
 500–24991.1(0.3–3.7)0.0(0.0-)
 2500–29990.9(0.4–2.1)1.4(0.7–2.9)
 3000–34991.0Referent1.0Referent
 3500–39991.1(0.7–1.9)1.3(0.8–2.2)
 4000–44991.8(1.0–3.1)0.9(0.4–1.8)
 4500–63000.7(0.2–2.8)0.4(0.1–2.8)
 Test for trend P=0.3 P=1.0
     
Birth length (cm)
 40–490.7(0.4–1.3)0.8(0.4–1.4)
 501.0Referent1.0Referent
 510.7(0.4–1.4)0.7(0.3–1.5)
 520.6(0.3–1.3)1.1(0.6–2.2)
 53–600.7(0.4–1.4)0.9(0.5–1.9)
 Test for trend P=0.6 P=0.2
     
Head circumference (cm) a
 <351.0(0.6–1.8)1.2(0.7–2.2)
 35–361.0Referent1.0Referent
 37+1.6(0.9–2.8)0.9(0.4–2.0)
 Test for trend P=0.1 P=0.5
     
Congenital malformations
 No1.0Referent1.0Referent
 Yes3.7(1.7–8.0)0.7(0.1–4.7)
     
Maternal age (years)
 <200.6(0.2–2.0)0.8(0.3–2.4)
 20–241.0(0.6–1.6)0.9(0.6–1.6)
 25–291.0Referent1.0Referent
 30–340.9(0.5–1.5)0.6(0.3–1.1)
 35+1.0(0.5–2.0)0.6(0.3–1.5)
 Test for trend P=0.9 P=0.2
     
Parity
 11.0Referent1.0Referent
 2–31.0(0.6–1.5)0.8(0.5–1.3)
 4–52.0(1.0–3.8)0.6(0.2–1.8)
 6+2.3(0.6–9.5)1.1(0.2–8.0)
 Test for trend P=0.2 P=0.2
     
Pre-eclampsia b
 No1.0Referent  
 Yes2.3(1.0–5.2)  
     
Caesarean section
 No1.0Referent1.0Referent
 Yes1.2(0.6–2.3)0.9(0.4–2.1)
     
Paternal age (years)
 <251.1(0.6–1.9)1.8(0.9–3.5)
 25–290.9(0.5–1.5)1.4(0.8–2.6)
 30–341.0Referent1.0Referent
 35–390.8(0.4–1.6)1.4(0.7–2.9)
 40+0.6(0.2–1.5)0.9(0.3–2.5)
 Test for trend P=0.4 P=0.1

Head circumference has been recorded since 1978.

All cases were diagnosed below 18 months of age.

Analyses of the study cohort stratified by age below and above 12 months did not reveal results substantially different from those described above (data not shown).

Discussion

Analyses of the relations between birth and parental characteristics and the risk of neuroblastoma in a large Norwegian cohort suggested that some of these factors may have an influence. In children below the age of 18 months, there was an increased risk among those with congenital malformations and also a suggestion of increased risk when the mother had pre-eclampsia. One of the major strengths of this study is the use of large health registries, covering the total population of Norway, to get reliable data on birth and parental characteristics and cancer occurrence. Reporting of cancer cases to CRN has been compulsory since the early 1950s, and the reporting has been almost complete and of high quality (Cancer Registry of Norway, 2007). Medical Birth Registry of Norway is also based on compulsory notification of every birth or late abortion from 16 weeks of gestation onwards. Medical Birth Registry of Norway includes demographic information on the parents, the mother's health before and during pregnancy, complications during pregnancy and delivery, length of pregnancy as well as information on the infant, including birth defects and other perinatal problems (Irgens, 2000). Within these data sources, we created a large study cohort of 2.1 million children, with a mean follow-up time of almost 12 years, to study the relations between pre- and perinatal factors and neuroblastoma. Nevertheless, only 178 cases were diagnosed, illustrating the rarity of this tumour. Although some estimates different from unity were discovered, the CIs were wide. In general, children with congenital malformations have an increased risk of cancer (Bjørge ). In our data, there was an increased risk of neuroblastoma in children with any congenital abnormality. A recent report from the Children's Oncology Group study showed an increased neuroblastoma risk with increasing number of congenital malformations, particularly genitourinary and cardiac anomalies (Menegaux ). Similar findings were reported from the California Cancer Registry study (Urayama ). Also other birth defects have been associated with the risk of neuroblastoma (Narod ). The malformations diagnosed in the eight neuroblastoma cases in our study had the following organ system distribution: heart and blood vessels (one), lip and palate (one), digestive system (two), urinary organs (one), musculoskeletal system (two) and multiple abnormalities (one). The literature dealing with pre- and perinatal risk factors for neuroblastoma has been largely inconclusive (Hamrick ; Schuz ). One recent case-cohort and two relatively recent case-control studies from the US have, however, suggested that certain perinatal factors may be associated with risk. In a study from birth and cancer registries in Minnesota, a maternal history of one fetal loss, maternal drug use and small size for gestational age were associated with neuroblastoma (Johnson ). In a study from the California Cancer Registry, associations with a number of birth characteristics were observed, including child's race/ethnicity, gestational age/birth weight, caesarean section delivery and maternal pregnancy history (Urayama ). In another study from the New York State Cancer Registry, pre- and post-term gestations were associated with a significant reduction in risk of neuroblastoma (Buck ). In mothers having pre-eclampsia during pregnancy, we found an increased risk of borderline significance in children below the age of 18 months. However, no strong associations have previously been found with diseases/conditions during pregnancy, as pre-eclampsia (Buck ; Hamrick ). In summary, in a huge population-based cohort study, we found that certain birth and parental characteristics may influence the risk of neuroblastoma, but no strong associations were established.
  13 in total

Review 1.  The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years.

Authors:  L M Irgens
Journal:  Acta Obstet Gynecol Scand       Date:  2000-06       Impact factor: 3.636

2.  Risk factors for neuroblastoma at different stages of disease. Results from a population-based case-control study in Germany.

Authors:  J Schüz; U Kaletsch; R Meinert; P Kaatsch; C Spix; J Michaelis
Journal:  J Clin Epidemiol       Date:  2001-07       Impact factor: 6.437

Review 3.  Screening for neuroblastoma.

Authors:  S N Huddart; J R Mann
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

4.  Congenital anomalies and childhood cancer in Great Britain.

Authors:  S A Narod; M M Hawkins; C M Robertson; C A Stiller
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

5.  Perinatal factors and risk of neuroblastoma.

Authors:  G M Buck; A M Michalek; C J Chen; P C Nasca; M S Baptiste
Journal:  Paediatr Perinat Epidemiol       Date:  2001-01       Impact factor: 3.980

6.  Time trends of cancer incidence in European children (1978-1997): report from the Automated Childhood Cancer Information System project.

Authors:  Peter Kaatsch; Eva Steliarova-Foucher; Emanuele Crocetti; Corrado Magnani; Claudia Spix; Paola Zambon
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

7.  Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project.

Authors:  Claudia Spix; Guido Pastore; Risto Sankila; Charles A Stiller; Eva Steliarova-Foucher
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

8.  Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  S E Hamrick; A F Olshan; J P Neglia; B H Pollock
Journal:  Paediatr Perinat Epidemiol       Date:  2001-10       Impact factor: 3.980

9.  Birth characteristics and risk of neuroblastoma in young children.

Authors:  Kevin Y Urayama; Julie Von Behren; Peggy Reynolds
Journal:  Am J Epidemiol       Date:  2006-12-12       Impact factor: 4.897

10.  Perinatal characteristics and risk of neuroblastoma.

Authors:  Kimberly J Johnson; Susan E Puumala; John T Soler; Logan G Spector
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

View more
  2 in total

Review 1.  Pediatric cancer risk in association with birth defects: A systematic review.

Authors:  Kimberly J Johnson; Jong Min Lee; Kazi Ahsan; Hannah Padda; Qianxi Feng; Sonia Partap; Susan A Fowler; Todd E Druley
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

2.  Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada.

Authors:  Louise Hayes; Nermine Basta; Colin R Muirhead; Jason D Pole; Paul Gibson; Bruna Di Monte; Meredith S Irwin; Mark Greenberg; Deborah A Tweddle; Richard J Q McNally
Journal:  Environ Health       Date:  2022-03-07       Impact factor: 5.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.